Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules Versus Fluconazole and Placebo in the Treatment of Acute Vulvovaginal Candidiasis Episodes in Subjects With Recurrent Vulvovaginal Candidiasis

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules Versus Fluconazole and Placebo in the Treatment of Acute Vulvovaginal Candidiasis Episodes in Subjects With Recurrent Vulvovaginal Candidiasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oteseconazole (Primary) ; Fluconazole
  • Indications Vulvovaginal candidiasis
  • Focus Registrational; Therapeutic Use
  • Acronyms ultraVIOLET
  • Sponsors Mycovia Pharmaceuticals

Most Recent Events

  • 25 Aug 2022 Results presented in the Mycovia Pharmaceuticals Media Release.
  • 18 Jul 2022 Results published in the American Journal of Obstetrics and Gynecology
  • 28 Apr 2022 According to a Mycovia Pharmaceuticals media release, U.S. Food and Drug Administration (FDA) approved VIVJOA (oteseconazole capsules), an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential. VIVJOA's FDA approval is based upon the positive results from two global, pivotal VIOLET studies and one U.S.-focused ultraVIOLET study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top